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Abstract: Developing targeted therapies based on patients’ baseline characteristics and genomic profiles such
as biomarkers has gained growing interests in recent years. Depending on patients’ clinical characteristics, the
expression of specific biomarkers or their combinations, different patient subgroups could respond differently to
the same treatment. An ideal design, especially at the proof of concept stage, should search for such subgroups and
make dynamic adaptation as the trial goes on. When no prior knowledge is available on whether the treatment
works on the all-comer population or only works on the subgroup defined by one biomarker or several biomarkers,
it’s necessary to incorporate the adaptive estimation of the heterogeneous treatment effect to the decision-making
at interim analyses. To address this problem, we propose an Adaptive Subgroup-Identification Enrichment Design,
ASIED, to simultaneously search for predictive biomarkers, identify the subgroups with differential treatment effects,
and modify study entry criteria at interim analyses when justified. More importantly, we construct robust quantitative
decision-making rules for population enrichment when the interim outcomes are heterogeneous in the context of a
multilevel target product profile, which defines the minimal and targeted levels of treatment effect. Through extensive
simulations, the ASIED is demonstrated to achieve desirable operating characteristics and compare favorably against
alternatives.
Key words: Adaptive enrichment design, Bayesian subgroup identification, Biomarker, Decision-making, Multilevel
target product profile.
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21. Introduction
Decision-making is a critical step for early-phase drug development, aiming to advance
promising drugs for further development and stop inferior drugs. Traditionally, decisions are
usually based on a significant p-value, e.g., the rejection of the null hypothesis in a Simon
two-stage design (Simon, 1989) would warrant further development of the drug. However, a
rejection of the null hypothesis may not necessarily support a desired treatment effect (Ratain
and Karrison, 2007). Furthermore, in the context of a multilevel target product profile (TPP),
which defines the minimal and targeted levels of treatment effect, more complex decisions
are needed. Such a TPP framework has been used routinely throughout clinical development
since it addresses the challenges when a drug effect cannot be represented well by a single
threshold (Frewer et al., 2016; Pulkstenis et al., 2017). Lalonde et al. (2007) first formulated
a Go/Pause/Stop decision framework by defining a lower reference value (LRV) and a target
value (TV), where LRV represents a “dignity” line for developing a drug and TV represents a
desired clinical improvement of commercial viability. Frewer et al. (2016) illustrated how the
Go/Pause/Stop decisions in the paper of Lalonde et al. (2007) were calculated for a Phase II
study and how the operating characteristics were assessed to ensure robustness. Pulkstenis
et al. (2017) extended the Lalonde framework by allowing to incorporate historical data prior
to calculating probabilities of Go/Pause/Stop. However, these approaches were developed
based on the assumption that the treatment effect was homogeneous among patients, limiting
their applicability in many diseases where heterogeneous treatment effect might exist.
Depending on patients’ clinical characteristics, the expression of specific biomarkers or
their combinations, it has become well known that there exists heterogeneity in treatment
effects across patient subpopulations when given the same treatment in many diseases. Thus,
it is essential to take into account potentially heterogeneous treatment effects in clinical trial
designs or data analyses when making a decision. For instance, breast cancer patients with an
enriched HER2 pathway were found to respond well to the medication trastuzumab (Hudis,
2007), while other subtypes of breast cancers do not. Another example is that treatments
with EGFR antibodies are not recommended for KRAS mutated colorectal cancer patients
as they are usually resistant to anti-EGFR treatment (Misale et al., 2012). Therefore, it is
very important at the proof-of-concept stage of drug development to identify the biomarkers
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that have interaction effects with the treatment and are predictive of the subgroups that are
more likely to respond to the treatment.
For situations where the predictive biomarkers are hypothesized but not proved, i.e.,
it is not clear whether the new therapy works for all-comers or a subpopulation, adaptive
enrichment designs have been developed to evaluate the treatment effect and thereby modify
the eligibility criteria at interim analyses in an attempt to identify the right population for
the new therapy. Patients exhibiting the desired treatment effects are referred to as the
“enriched population.” Wang et al. (2007) and Karuri and Simon (2012) compared the
active versus placebo by evaluating the treatment effectiveness of biomarker positive- and
negative- subgroups at an interim analysis, allowing for terminating the enrollment of the
biomarker negative subgroup. Simon et al. developed a class of adaptive enrichment designs
to adaptively update the eligibility criteria, they then extended this work by developing a
frequentist/Bayesian model for decision making using a formal hypothesis test at the end of
the trial to preserve type I error (Simon and Simon, 2013, 2017). See, for example, Wang
and Huang for a review of adaptive enrichment designs (Wang and Hung, 2013).
Most of these enrichment designs use a set of biomarkers to pre-define subgroups and
then test if there are differential therapeutic effects on these pre-defined subgroups. However,
pre-defining subgroups can be problematic if the pre-defined biomarkers are not predictive
or the cutoff values for the predictive biomarkers are incorrect. Therefore, an enrichment
design that allows the discovery and estimation of subgroups during the clinical trial is highly
desirable. Subgroup identification involves two major tasks: identify predictive biomarkers
and determine the optimal cutoff values for predictive biomarkers. Foster et al. (2011)
developed a random forest-based algorithm to find subgroups by searching biomarker regions
where the treatment effect is larger than the average effect on the whole population. Lipkovich
et al. (2011) developed SIDES (subgroup identification based on differential effect search),
which makes use of the classification and regression tree (CART) (Breiman et al., 1984)
to recursively split a patient set such that one of the halves from each split has maximal
treatment effect relative to the other half. Loh et al. (2015) and Loh et al. (2016) proposed
a regression tree approach, GUIDE, to first decide which biomarkers to split on through
the use of χ2 tests, and then identify the optimal cutoff values for the selected biomarkers.
4Xu et al. (2014) developed SUBA, a Bayesian subgroup-based adaptive design, to allocate
the patients to their superior treatments using a random partition model that splits the
biomarker space by the observed biomarker’s median value, which generally is not the
optimal cutoff for a predictive biomarker. Guo et al. (2017) extended SUBA (i.e., SCUBA) by
allowing the biomarker space to be split using hyperplanes that construct linear boundaries,
providing a more flexible partition model. All of these methods either target the subgroup
identification using the retrospective clinical trial data, or focus on subgroup identification
for patient allocations during the trial. They have not been directly utilized in clinical trial
enrichment designs to modify the study entry criteria during interim analyses in the context
of a multilevel TPP.
Applying the Lalonde framework (Lalonde et al., 2007) in the context of a multilevel
TPP to construct enrichment decision rules in a heterogenous population is challenging and
complicated, since one needs to deal with heterogeneity in treatment effect across patient
subpopulations. To our best knowledge, there is no such precedent thus far. In this paper, we
propose an adaptive subgroup-identification enrichment design (ASIED), utilizing patients’
biomarker profiles and outcomes as they become available to create a design with learning,
adapting and enriching capacity. ASIED searches for subgroups among a set of biomarkers
using interim accumulated data obtained from all-comers rather than predefining subgroups
and allows the entry criteria to be modified to enroll subjects with specific clinical character-
istic or biomarker signature who are more likely to respond to the treatment, enabling better
learning of the treatment effect on the enriched population. The biomarker-defined subgroups
are not fixed upfront – we assume a prior on the partition to classify the patients into
subgroups and then learn the cutoff values using observed response data. Building upon Xu
et al. (2014) and Guo et al. (2017), ASIED uses a flexible Bayesian model as the core search
algorithm that can handle biomarkers of varying forms (continuous, binary, categorical, or
ordinal) and different types of response outcomes (binary, categorical, continuous). The
method can be easily extended to model other types of outcomes, such as counting and
survival outcomes. More importantly, we construct a decision-making framework to make
informed decisions, such as continuing with all-comers or enriching to a subpopulation. The
possible decisions include: a “Go” decision for all-comers, a “Go” decision for the identified
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subgroup with enhanced treatment effect, a “Stop” decision for all-comers due to futility, or
conduct one more interim analysis when the interim result is inconclusive.
The key novelty of ASIED is to combine the tasks of “subgroup identification” and
“enrichment” to create an adaptive enrichment design engine that enables more efficient
learning about the investigational drug’s efficacy in the identified subpopulation through a
set of decision-making rules in the context of a multilevel TPP. The posterior inference
for subgroups with enhanced treatment effects under the proposed Bayesian model will
lead to the modification of study enrollment criteria. Therefore, more patients with the
characteristics in the identified subgroup can be enrolled to the study as the trial continues
after the interim analysis. In summary, ASIED represents the first effort in the literature
to conduct subgroup discovery, evaluation, and adaptive modification of study enrollment
criteria simultaneously using a flexible Bayesian searching algorithm and a probabilistic
decision-making framework.
This paper proceeds as follows. We first introduce the motivating trial in Section 2.
The proposed ASIED design with a decision-making framework is described in Section 3.
We elaborate the proposed Bayesian random partition model for subgroup identification in
Section 4 with simulation studies. Section 5 presents simulation studies that examine the
operating characteristic of the ASIED in the motivating AD symptom improvement POC
study. We conclude with a discussion in Section 6.
2. Motivating Trial
We consider a placebo-controlled, double-blind proof-of-concept (POC) study for an inves-
tigational drug on patients with Alzheimer’s disease (AD) for symptom improvement. The
primary efficacy endpoint is the change from baseline to final observation on the total score of
13-item Alzheimer’s disease Assessment Scale – Cognitive Subscale (ADAS-cog) in a 12-week
study. Previous research has suggested a number of biomarkers that might predict treatment
effect on AD. These biomarkers are apolipoprotein E (APOE)-4 genotype and allele status,
plasma amyloid precursor protein β (Aβ), and cerebrospinal fluid (CSF) β-site amyloid
precursor protein (APP)-cleaving enzyme 1 (BACE1). It is plausible that the investigational
drug only has a clinically meaningful effect on a subpopulation that is qualified by one of the
6biomarkers or a combination of several biomarkers listed above. The objective of this clinical
trial is to test whether the investigational drug has efficacy of AD symptom improvement on
all-comers or on a biomarker-defined subpopulation, and if latter, to learn more about the
efficacy of the drug on the subpopulation in the same study by adaptive enrichment.
At the beginning, patients diagnosed with probable AD and meeting entry criteria will be
enrolled and equally assigned to the placebo or the investigational drug. Baseline biomarkers
data will be collected. At the pre-specified interim analysis, accumulating ADAS-cog total
scores are utilized to assess whether the treatment has effect on all-comers and search for
potential subgroups with enhanced treatment effects compared to all-comers. When such a
subgroup is ascertained by pre-specified decision rules, study entry criteria will be modified
so that only the patients with the characteristics in the identified subpopulation will be
enrolled in the rest of the study. The enrichment in the middle course of the study will
allow more information to be obtained for the subpopulation to inform next step of clinical
development.
Previous research reported that the pooled treatment effect of Cholinesterase Inhibitors
(approved AD symptom improvement therapies) vs. placebo on mild-to-moderate AD pa-
tients was 2.37 (Birks, 2006). In this paper, the motivating AD trial is used as the background
for simulation studies. To set up simulation scenarios and Go/No-Go decision rules in the
proposed adaptive enrichment design, we assume that LRV=2.37 is the minimum target and
a 30% gain over the pooled effect (TV=3.08) is the desired target when developing a new
molecular for the AD symptom treatment.
3. Adaptive Subgroup-Identification Enrichment Design (ASIED)
Assume we have a maximum sample size of N patients and T candidate treatments indexed
by t = 1, . . . , T . In the motivating AD trial, T = 2, where t = 1 represents the placebo and
t = 2 represents the investigational drug. All patients are equally randomized to placebo
and investigational drug. The design can be easily extended to multiple treatments. In this
section, we propose an adaptive enrichment design that applies a set of decision rules to
determine whether the study population should be enriched after subgroup identification.
In the motivating AD trial, we have a lower reference value (LRV) and a target value
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(TV) to characterize the desired efficacy, in which LRV represents a clinically meaningful
minimum treatment effect that is a “dignity” line for developing a drug and TV represents
a desired targeted effect increment of the new drug (TV > LRV). Let δ∆ represent the
estimated treatment effect for a given subgroup ∆ under a probability model. Note here we
do not make any specific assumptions about the subgroup identification model, except for
the existence of such a model. Then the probability of the estimated treatment effect being
larger than LRV for a given subgroup ∆ can be denoted by Pr(δ∆ > LRV). Similarly for
the probability of the estimated treatment effect being larger than TV for a given subgroup:
Pr(δ∆ > TV).
We define three decision outcomes for a subgroup ∆: “Go” if Pr(δ∆ > LRV) > ξ1;
“Stop” if Pr(δ∆ > LRV) < ξ1 and Pr(δ∆ > TV) < ξ2; “Gray zone” otherwise. The tuning
parameters ξ1 and ξ2 are chosen by simulations to obtain a design with desirable operating
characteristics. In Section 5, we will illustrate how one may calibrate these parameters.
The ASIED will be conducted as follows.
• Start the trial by enrolling all-comers denoted by Ω. All subjects are equally randomized
to the placebo and the investigational drug.
• Interim analyses. At the time when the data from the first n1 subjects become available,
an interim analysis will be conducted. Specifically, we search for subgroups with enhanced
treatment effect, and apply the following rules to make decisions.
(1) If the treatment effect is a “Go” for all-comers, that is, Pr(δΩ > LRV) > ξ1, we continue
the trial with the all-comer population until N subjects are enrolled.
(2) If the treatment effect is a “Stop” for all-comers, but a “Go” for a subgroup ∆, that
is, Pr(δΩ > LRV) < ξ1, Pr(δΩ > TV) < ξ2, and Pr(δ∆ > LRV) > ξ1, we enrich the
study population to this subgroup by restricting the entry into the clinical trial to only
patients with x ∈ ∆ for the remaining sample size (e.g., N − n1). Here x ∈ ∆ indicates
that the patient with biomarker profile x belongs to the subgroup ∆.
(3) If the treatment effect is a “Stop” for all-comers and all possible subgroups, that is,
Pr(δΩ > LRV) < ξ1, Pr(δΩ > TV) < ξ2, Pr(δ∆ > LRV) < ξ1, and Pr(δ∆ > TV) < ξ2
for any subgroup ∆, then we stop the trial early due to futility.
(4) If the treatment effect for all-comers is in “Gray zone”, that is, Pr(δΩ > LRV) < ξ1
8and Pr(δΩ > TV) > ξ2, we continue the trial with the all-comer population with n2
(n1 + n2 < N) more patients and conduct a second interim analysis with potential
outcomes of Step 1, 2, or 3 at the second interim.
(5) If the treatment effect for all-comers is “Stop”, but there is one subgroup ∆ in “Gray
zone”, we enrich study population to this subgroup by restricting the entry into the
clinical trial to only patients with x ∈ ∆ until n2 more patients are enrolled. Then we
conduct a second interim analysis with the following potential outcomes.
– If the treatment effect is a “Stop” for the enriched subpopulation ∆, we stop the
trial due to futility.
– Otherwise, we continue the trial with the enriched subpopulation ∆ until all N
subjects are enrolled to the study.
• Final recommendation of the drug. When the trial is completed, there are three possible
final recommendations of the drug denoted by a ∈ {0, 1, 2}, with a = 2 denoting a
recommendation of “Go” for all-comers; a = 1 denoting a recommendation of “Go” for a
subgroup; otherwise a = 0 (including the scenarios where the investigational drug fails to
demonstrate effect for all-comers nor for any sub-population, the treatment effect is in the
”Gray Zone” for all-comers, or it is “Stop” for all-comers but in the ”Gray Zone” for a
subgroup).
Figure 1 summarizes the decision-making framework for the ASIED.
[Figure 1 about here.]
4. A Bayesian Subgroup Identification Model
Recall that in Section 3 we assume there exists a subgroup identification model, which
can identify the subgroup with enhanced treatment effect based on patients’ biomarker
profiles and responses at each interim analysis. In our implementation we introduce a flexible
Bayesian model as the core search algorithm that can handle biomarkers of varying forms and
different types of response outcomes, building upon the methods proposed in Xu et al. (2014)
and Guo et al. (2017). The proposed model will be easy to implement and accurately identify
the subgroup with enhanced treatment effect when the sample size N is small. However,
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any alternative subgroup identification model that learns about enhanced treatment effects
by including treatment by covariate interactions, could be used. For example, when the
sample size is large, machine learning-based methods such as random forest (Foster et al.,
2011) or more flexible Bayesian methods such as Bayesian additive regression trees (BART)
(Chipman et al., 2010) could be incorporated into the decision-making framework of the
proposed ASIED.
Assume we have a maximum sample size of N patients that are indexed by i = 1, . . . , N ,
and suppose there are T candidate treatments indexed by t = 1, . . . , T . Let zi = t denote
that patient i is assigned to treatment t. Assume that we have K biomarkers that are
potential predictive biomarkers identified from the investigational drug’s mechanism of action
or disease clinical presentation. We assume that a biomarker k can be binary, ordinal,
categorical, or continuous, where k = 1, . . . , K. Denote xi = (xi1, . . . , xiK)
′ and yi to be
the biomarker profile and the response outcome of the ith patient, respectively.
Let Ω denote the biomarker space. We say that a partition is a family of subsets Π =
{S1, · · · , Sm, · · · , SM}, where the Sm’s are mutually disjoint and their union is Ω. Here the
number M of subsets is random. The partition on the biomarker space induces a partition of
the patients. If xi ∈ Sm, we say patient i with biomarker profile xi belongs to subgroup m.
We will construct a prior probability measure for Π in the next section. Below we consider
the sampling model of yi of different types conditional on xi and Π, using binary outcomes
and continuous outcomes as examples. It can be easily extended to other types of outcomes,
such as categorical or survival outcomes. Let Θ denote the parameters in the sampling model.
Denote Y n = (y1, . . . , yn), Xn = {xi}ni=1, and Zn = (z1, . . . , zn).
Binary outcomes. Let yi ∈ {0, 1} and θt,m be the response rate of patients in subgroup m
under treatment t. In this case, Θ = {θt,m}T, Mt=1,m=1. We assume
p(yi = 1 | zi = t,Π,xi ∈ Sm) = θt,m.
The likelihood function is simply the product of n Bernoulli probability mass functions. We
assign the prior θt,m | Π iid∼ Beta(at, bt), where Beta(at, bt) denotes a beta distribution with
mean at/(at + bt).
Continuous outcomes. Let yi ∈ R and θt,m be the mean response of patients in subgroup m
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under treatment t. We assume
yi | zi = t,Π,xi ∈ Sm ∼ N(θt,m, σ2).
The likelihood can be written as follows:
p(Y n |Xn,Zn,Θ,Π) =
T∏
t=1
M∏
m=1
∏
{i:zi=t,xi∈Sm}
(2pi σ2)−1/2 exp{− 1
2σ2
(yi − θt,m)2}. (1)
We assign the conjugate prior p(θt,m, σ
2) = p(θt,m|σ2)p(σ2) with θt,m|σ2 ∼ N(θ0, σ2κ0 ) and
σ2 ∼ IG(ν0
2
,
SS20
2
), where SS20 = ν0σ
2
0.
The joint model can be written as follows,
p(Y n,Θ,Π |Xn,Zn) ∝ p(Y n |Xn,Zn,Θ,Π) p(Θ |Xn,Zn,Π) p(Π | c)p(c), (2)
where c denotes the parameters in the prior model that describes the random partition Π.
We have introduced the sampling model and the priors for Θ. In the next section, we will
discuss the prior of Π and c.
4.1 Prior of Partition
We propose a tree-type random partition on the biomarker space Ω to define random
biomarker subgroups. We build partitions via a tree of recursive splits: each node of the
tree represents a subset of Ω. The final leaves of the tree are the partitioning sets {Sm}Mm=1.
At each node the tree is either pruned or the corresponding subset is further split into two
siblings. In the latter case, the two siblings are defined by a plane orthogonal to a randomly
selected axes of Ω, say the axis of the k-th biomarker. In other words, through a sequence
of splits, each of which selects a biomarker k first and then splits the space of xk into two
subspaces, we generate a partition set of Ω as the collection of the resulting subsets. For
the motivating AD trial, we limit the partition to at most four biomarker subgroups due to
the small sample size, and hence there are no more than two rounds of random splits in the
random partition. This constraint is imposed to avoid resulting in subgroups with too few
patients.
Figure 2) illustrates the procedure of random partition using a simple example with two
rounds of splits and two continuous biomarkers on [−1, 1]2. In each round, for each of the
current subsets, we split along a biomarker k with probability νk or choose not to split with
probability ν0,
∑K
k=0 νk = 1. If an ancestor subset S is split into two subsets by the k
th
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biomarker, then the resulting subsets are {i : xik 6 ck(S)} and {i : xik > ck(S)}, where
ck(S) is the threshold by which the subset is being split. We will discuss the prior of ck(S)
later. For example, in Figure 2, biomarker 1 is chosen in the first round and the patients are
split into U1 = {i : xi1 6 0.5} and L1 = {i : xi1 > 0.5}. Here the subindex 1 denotes that
biomarker 1 is chosen to split; U and L denote that the measurements are smaller and larger
than the threshold, respectively. In round 2, we split the subgroup U1 into two biomarker
subgroups UU11 and UL11 by choosing biomarker 1 with threshold 0 and split the subgroup
L1 into two biomarker subgroups LU12 and LL12 by choosing biomarker 2 with threshold -0.2.
Note that the ordering of letters U and L are matched with the ordering of the biomarker
index. Therefore, at the end, we have the partition Π = {UU11, UL11, LU12, LL12}, which
corresponds to four biomarker subgroups.
[Figure 2 about here.]
For a given subset S, if biomarker k is selected with probability νk from a set of available
biomarkers to split at threshold ck(S), the prior of ck(S) depends on the type (continuous,
binary, categorical, or ordinal) of biomarker k. By “available”, we mean that the split rules
would not lead to empty subgroup. For example, if a binary biomarker was used in one round
of split, then it would no longer be available for splitting at nodes below it. We describe the
split rules for determining a partition of the biomarker space for various types of biomarkers,
including continuous, binary, categorical, and ordinal biomarkers as follows.
• If biomarker k is binary, the split will be deterministic and we denote Uk = {i : xik = 0}
and Lk = {i : xik = 1}. Therefore p(ck) = 1.
• If biomarker k is continuous, denote Uk = {i : xik 6 ck} and Lk = {i : xik > ck}. We
assume p(ck) = Uniform(min{xik}Ni=1,max{xik}Ni=1).
• If biomarker k is ordinal, let Vk denote the number of labels that biomarker k has. Let ck
denote the endpoint of the left partition, e.g., if Vk = 5 and ck = 3, the left partition is
{1, 2, 3} and the right partition is {4, 5}. In this way we denote Uk = {i : xik 6 ck} and
Lk = {i : xik > ck}. Moreover, if ck = Vk, it is equivalent to not splitting, which has been
considered with probability ν0. Therefore, p(ck) =
1
Vk−1 .
• If biomarker k is categorical, let Vk denote the number of categories corresponding to
biomarker k. Let ck denote the elements in one subset Uk. The remaining elements are
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stored in the other subset Lk. The ck are elements of the powerset of {1, 2, · · · , Vk} without
the empty-set or the full set. There are hence 2Vk−2 options for ck. Note that the choice of
ck is symmetric: we may flip ck and its complement, leading to the same partition. Thus,
p(ck) =
2
2Vk−2 .
In the Supplement A, we describe the detailed split rules using two rounds of splits as
an example by taking into account various types of biomarkers.
4.2 Posterior Inference
Markov chain Monte Carlo (MCMC) method is used to obtain the posterior samples of the
parameters based on the joint model (2). Each iteration of the MCMC simulations consists
of the following transition probabilities. Sampling θt,m is straightforward due to the use
of conjugate priors. For example in the binary outcome case, we can easily compute that
p(θt,m | Y n,Π,Zn) ∼ beta(ntm1 + a, ntm0 + b), where ntmy =
∑
i I(xi ∈ Sm, zi = t, yi = y),
y = 0, 1. In the joint model (2), p(Π | c) = 1 since c decides the partition Π deterministically.
Sampling the biomarkers k’s that split the patient subsets might change the number of
subgroups M , leading to the change of the dimension of c, since we allow to choose not
to split. Hence we make use of a two-step Metropolis-Hasting sampler to first update the
thresholds ck’s conditional on the selected biomarkers, then update both biomarkers k’s
and their thresholds ck’s together to ensure fast convergence. We defer the detailed MCMC
derivations for all types of outcomes in the Supplement B.
4.3 Subgroup Identification
Since a random distribution is proposed as a prior on the partition, summarizing a distribu-
tion over the random partition and then identifying the subgroups with enhanced treatment
effects become challenging. Reporting subgroups with enhanced treatment effects hinges on
the discovery of regions in the biomarker space in which one treatment outperforms the
others. Assume n patients have been treated and their responses have been obtained at the
interim analysis. Denote Dn = {Y n,Xn,Zn}. We define an equally spaced grid of Dk values
{xk1, . . . , xkDk} for biomarker k in the biomarker space, then take the Cartesian product of
the grids across all K biomarkers to obtain a K-dimensional grid x˜d of size
∏
kDk points.
For example, if biomarker k is continuous on [-1, 1], we can choose Dk = 20 equally spaced
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points on [-1, 1]; if biomarker k is binary, then Dk = 2. Each grid point d represents a
possible biomarker profile. For patient i with biomarker profile x˜d, we can compute the
posterior predictive distribution of yi by
p(yi | zi = t,xi = x˜d,Dn) =
∫
p(yi | Θ, zi = t,xi = x˜d)p(Θ | Dn)dΘ.
In the MCMC samples, the bth iteration after burn-in generates a posterior sample {Θ(b),Π(b), c(b)},
which defines a partition set Π(b) = {S(b)1 , . . . , S(b)M(b)} and their corresponding response pa-
rameters. We can easily calculate the posterior mean response of the patient with biomarker
profile x˜d at iteration b as θ
(b)
t,m if zi = t and x˜d ∈ S(b)m , here B is the number of saved MCMC
iterations after burn-in.
In the motivating AD trial, we assume that t = 1 represents placebo and t = 2 represents
the investigational drug. The posterior estimated treatment effect for a given subgroup ∆ at
iteration b can be represented by
δ
(b)
∆ =
1
n∆
∑
d:x˜d∈∆
(θˆ
(b)
2,d − θˆ(b)1,d),
where n∆ denotes the number of grid points that fall in the subgroup ∆. Denote the posterior
probability of treatment effect being larger than LRV for a given subgroup ∆ by Pr(δ∆ >
LRV). We can easily compute
Pr(δ∆ > LRV) =
1
B
∑
b
I
[
δ
(b)
∆ > LRV
]
,
which can be then used for the Go/Stop/Gray zone decision-making described in Section 3.
If the goal is to identify the subgroup of patients whose posterior probability of treatment
effect being larger than LRV is bigger than a threshold ξ, we can represent such a subgroup
as {∆ : Pr(δ∆ > LRV) > ξ}.
4.4 Simulation Studies on Subgroup Identification
We conducted simulation studies to evaluate the proposed Bayesian random partition (BayRP)
model on subgroup identification. We designed simulation scenarios based on the motivating
AD trial as described in Section 2 and assumed that K = 4 baseline biomarkers were
available for each patient and p(νk) = 1/5, k = 0, 1, . . . , 4, indicating a uniform prior on the
biomarker selection. The priors on the parameters in c were introduced in supplement A.
We considered four scenarios and simulated 100 trials for each scenario. In the motivating
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AD trial, the first interim analysis will be conducted when 100 subjects have finished Week
12 visit of the study. Therefore, the sample size n = 100 was set for each scenario to test
if BayRP can accurately identify subgroups with enhanced treatment effects. With equal
randomization to the placebo or the investigational drug, this would give us approximately
50 per group for the interim analysis.
In the first three scenarios, we assumed all the biomarkers were continuous and generated
xik from Uniform(−1, 1), i = 1, . . . , n and k = 1, . . . , 4. In scenario 1, we assumed only
the first biomarker was related to the response and yi = 0.75 + 0.25I(zi = 2) + 3I(xi1 >
−0.4)I(zi = 2)+i. In scenario 2, the first two biomarkers were related to the response and the
outcomes yi’s were generated from yi = 0.75+0.25I(zi = 2)+3I(xi1 < 0.3, xi2 > −0.4)I(zi =
2) + i. In scenario 3, we assumed yi = 0.75 + 0.25I(zi = 2) + 1.5I(xi1 > 0.4)I(zi = 2) + i. In
scenario 4, we considered three continuous biomarkers generated from Uniform(−1, 1) and
one binary biomarker generated from Bernoulli(0.5). The response yi’s were generated from
yi = 0.75 + 0.25I(zi = 2) + 3.5I(xi1 = 1, xi2 > −0.4)I(zi = 2) + i. Here i ∼ N(0, 1).
Define the true effective subgroup as So =
{
i : [E(yi | zi = 2,xi)− E(yi | zi = 1,xi)] >
LRV
}
. In the motivating AD trial, LRV=2.37 was used. The left column of Figure 3 shows
the simulated true effective subgroups in blue color for scenarios 1, 2, and 4. Note that we
have four biomarkers, but only biomarkers 1 and/or 2 are predictive to responses. Therefore,
we plot the true simulated effective subgroup versus biomarkers 1 and 2. Scenario 3 is not
shown since there is no effective subgroup.
[Figure 3 about here.]
We first report the effective subgroup estimated by the proposed Bayesian random parti-
tion (BayRP) model. For each simulated trial h, h = 1, . . . , 100, we denote δ
h,(b)
d = θˆ
h,(b)
2,d −θˆh,(b)1,d
to be the posterior estimated treatment effect of grid d with biomarker x˜d at iteration b in
trial h. The collection over all the MCMC iterations can be used to report the effective
subgroup. Denote δˆhd to be the probability that the treatment effect of the grid d with
biomarker x˜d is larger than LRV in trial h. Given a desired confidence ξ, we determine that
the grid d with biomarker x˜d belongs to the effective subgroup in trial h if
δˆhd =
1
B
∑
b
I(δ
h,(b)
d > LRV) > ξ. (3)
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Here we set ξ = 0.9. Then we define the estimated effective subgroup ∆ˆBayRP under BayRP
as the set of subjects whose posterior probability of the treatment effect being larger than
LRV are bigger than 0.9, which can be computed as
∆ˆBayRP =
{
d :
1
100
100∑
h=1
I(δˆhd > ξ) > 0.9
}
. (4)
That means, the estimated effective subgroup under repeated simulations by BayRP is a set
of subjects who belong to the effective subgroup in at least 90% of the simulated trials.
BayRP correctly identifies biomarkers 1 and 2 as important predictive biomarkers in all
scenarios. The second column of Figure 3 shows the estimated effective subgroup ∆ˆBayRP
versus biomarkers 1 and 2, represented by the grid points in blue for scenarios 1, 2, and 4.
As shown in Figure 3, the effective subgroups identified by the BayRP successfully recover
the simulation truth. Scenario 3 is a NULL case, there is no effective subgroup. The BayRP
identified ∆ˆBayRP = ∅, which matches the simulation truth.
For comparison, we implemented two alternative methods on subgroup identification for
each simulated trial: a Bayesian linear regression (LR) method and GUIDE (Loh et al.,
2015). Under the LR method, the outcomes were modeled as a Bayesian linear regression
considering all main effects and interaction effects between treatments and biomarkers:
yi | zi,xi = β0 + β1zi +αxi + γzixi + i,
where i
iid∼ N(0, σ2). We assumed non-informative conjugate priors, 1/σ2 ∼ Gamma(0.1, 0.1)
and (β0, β1,α,γ) ∼ MN(0, 20I), where Gamma(a, b) denotes a gamma distribution with
mean a/b, MN(µ,Σ) denotes a multivariate normal distribution with mean µ and covariance
Σ, and I denotes the identity matrix. The posterior samples were obtained by a Gibbs
sampling procedure. Since LR did not provide a formal way to report the effective subgroup
under repeated simulations, we estimated the effective subgroup under LR following (4)
under BayRP for a fair comparison. Specifically, we calculated the treatment effect q
h,(b)
d for
each grid d with biomarker xd at MCMC iteration b in trial h using the predicted values of
LR under two treatments, that is q
h,(b)
d = E
h,(b)(yd | zd = 2,xd)− Eh,(b)(yd | zd = 1,xd). We
determined that the grid d with biomarker x˜d belonged to the effective subgroup in trial h if
1
B
∑
b I(q
h,(b)
d > LRV) > ξ. Similar to (4), we then defined the estimated effective subgroup
∆ˆLR under LR as a collection of subjects who belong to the effective subgroup in at least 90%
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of the simulated trials. Under the GUIDE method, we downloaded GUIDE software (http://
www.stat.wisc.edu/~loh/guide.html, version 27.3) and applied the “Gi” algorithm with
the default parameter setting to construct 0-SE least-square regression tree. All biomarkers
as well as the treatment assignments were used to construct the tree. We ran GUIDE to the
simulated datasets and defined the effective subgroup as the set of subjects among all grid
points whose predictive treatment effects are larger than LRV. Then ∆ˆGUIDE under GUIDE
can be estimated in the same way as ∆ˆLR.
For the null scenario 3, both LR method and GUIDE successfully recover the simulated
truth, ∆ˆLR = ∆ˆGUIDE = ∅. The third and fourth columns of Figure 3 plot the estimated
effective subgroup by the LR method and GUIDE in scenarios 1, 2, and 4, respectively.
We can clearly see that LR cannot recover the simulated truths in these three scenarios
when an effective subgroup exists. In contrast, the effective subgroups estimated by GUIDE
have a large overlap with the simulated truths in scenarios 1 and 2, comparable to BayRP.
However, in scenario 4 where there is one binary predictive biomarker (i.e., biomarker 1) and
one continuous predictive biomarker (i.e., biomarker 2), GUIDE cannot identify any effective
subgroup.
In addition, we report the true positive rate (TPR) and true negative rate (TNR) of the
effective subgroup finding under BayRP, LR, and GUIDE. We define two quantities: 1) TPR
=
∑
{d:xd∈So}
∑100
h=1 I(xd ∈ ∆ˆ)/(|So| × 100), where |So| is the number of grid points in the
simulated true effective subgroup; 2) TNR =
∑
{d:xd /∈So}
∑100
h=1 I(xd /∈ ∆ˆ)/(|Ω \ So| × 100).
As shown in Table 1, all three methods achieve high TNR, but the BayRP achieves much
higher TPR compared to both the LR method and GUIDE, especially for scenario 4 where
TPR is 0.87 for BayRP and 0 for either LR or GUIDE. Scenario 3 is not included since there
is no effective subgroup.
[Table 1 about here.]
In summary, the proposed BayRP can accurately identify the predictive biomarkers and
the subgroup with enhanced treatment effect, building a solid foundation for the ASIED
trial design. Note that the subgroup identification model is independent of the adaptive
enrichment decision framework proposed in Section 3, and any subgroup identification model
such as random forest, SUBA, or BART could be implemented to the decision-making
Bayesian Enrichment Design 17
framework of the proposed ASIED. This makes ASIED a flexible adaptive enrichment design
that combines the tasks of “subgroup identification” and “enrichment.” We choose BayRP
since it is a robust Bayesian tree model but yields satisfactory performance when the sample
size is small, unlike other complex models requiring large sample sizes for accurate estimation,
such as SCUBA.
5. ASIED Operating Characteristics
In this section, we evaluate the performance of the proposed ASIED design on trial operating
characteristics via simulation studies. In each trial, the maximum sample size was N = 180
and subjects were equally randomized to the placebo or the investigational drug. We set
LRV=2.37 and TV=3.08, following the rationale provided in the motivating AD trial. The
first interim analysis would be conducted after n1 = 100 patients were enrolled. If a second
interim analysis is needed, n2 = 40. We assumed that K = 4 biomarkers were available for
each patient and p(νk) = 1/5, k = 0, . . . , 4, indicating a uniform prior on the biomarker
selection in the proposed BayRP on subgroup identification.
The decision-making framework depends on the parameters ξ1 and ξ2, which defines
decisions “Go”, “Stop”, and “Gray zone.” A practical implementation of the proposed design
should consider what would be acceptable decision risks to determine the tuning parameters
ξ1 and ξ2. To this purpose, we define three acceptable risks at the first interim analysis: false
stop risk (FSR), false go risk (FGR), and false enrich risk (FER). FSR is an acceptable risk
that a “Stop” decision is made at the first interim analysis when the truth is that there
exists an effective subgroup or the all-comer is effective. FGR is an acceptable risk that a
“Go” or “Gray zone” decision is made when the truth is that there is no effect in all-comers
or in any subgroup. FER is an acceptable risk that an effective subgroup is enriched at the
first interim analysis when the truth is that all-comers are effective. These risks could differ
for different drugs and with the attitude to risk for different companies. In our case design,
we set FSR=0.05, FGR=0.1, and FER=0.15. Note these values can be changed, as long as
they can be justified.
To evaluate the performance of ASIED in operating characteristics, we assumed that all
the biomarkers were continuous and generated from Uniform(−1, 1). The responses yi’s were
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generated from yi = 0.75+β0I(zi = 2)+β1I(xi1 > −0.4)I(zi = 2)+i, where i ∼ N(0, 0.52).
Here different values of β0 and β1 were selected to generate different scenarios. For example,
when β0 = 0.25 and β1 = 2.55, there exists an effective subgroup ∆ = {i : xi1 > −0.4} whose
treatment effect is larger than LRV but smaller than TV. We considered five scenarios, as
shown in Table 2.
[Table 2 about here.]
Determining ξ1 and ξ2. We first implemented ASIED design to the five scenarios at the
first interim analysis to determine ξ1 and ξ2 by controlling FSR, FGR, and FER. Table S1
in Supplement C presents the sensitivity analysis of the decisions for different combination
values of ξ1 and ξ2. With the guidance of the three pre-determined risks, we set ξ1 = 0.8 and
ξ2 = 0.1. More details are discussed in Supplement C.
Sensitivity analysis to sample size at the first interim analysis. To investigate the
impact of sample size at the first interim on the decision-making, we plot the estimated
probabilities of different decisions versus different sample sizes at the first interim analysis
for all five scenarios in Figure 4. As shown in Figure 4, the sample size n1 = 100 at the
first interim analysis yields satisfactory decision outcomes. For instance, when there exists
an effective subgroup (scenario 2), the probability of continuing the trial with an enriched
subpopulation increases as the sample size increases.
[Figure 4 about here.]
Operating characteristics. Now we are ready to evaluate the performance of ASIED
trial design in terms of operating characteristics. As described in Section 3, ASIED has three
possible final recommendations, with a = 2 denoting a recommendation of investigational
drug for all-comers; a = 1 denoting a recommendation of investigational drug for a subgroup;
and a = 0 denoting no recommendation for investigational drug. If the trial is stopped early
due to futility, ASIED records the terminal decision a = 0. We implemented the ASIED
to the five scenarios shown in Table 2. Table 3 reports the probabilities of the five interim
decisions and three final Go/Stop recommendations for each scenario under 100 repeated
simulations. As shown in Table 3, ASIED achieves desirable operating characteristics. For
example, when β0 = 0.25, β1 = 2.55, we recommend the investigational drug for an effective
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subgroup with probability 0.96 and recommend stop for the drug with probability 0.04; when
β0 = 0.25 and β1 increases to 2.83, we recommend the investigational drug for an effective
subgroup with probability 0.94 and for all-comers with probability 0.06.
[Table 3 about here.]
6. Conclusion
We develop a Bayesian random partition (BayRP) model to search for subgroups with
enhanced treatment effect and a novel enrichment design, ASIED, with a robust decision-
making framework that either allows the study to continue with all-comers or adapt to
a subpopulation with enhanced treatment effect based on the interim accumulated data.
BayRP is fully Bayesian, providing principled and coherent inference on the effective sub-
group identification. As shown in the simulation studies, BayRP is flexible and capable of
recovering the effective subgroups with various types of biomarkers. The rule for effective
subgroup report is also flexible, as we can tune the confidence level ξ in (3) depending on
the goal of the study.
More importantly, to the best of our knowledge, ASIED represents the first attempt
in the literature to create a set of comprehensive rules to guide enrichment decisions at
interim in the framework where a multilevel target profile (LRV and TV) is incorporated.
The merit of using inferred treatment effect and probability statement to make enrichment
decisions at interim or decisions about the drug’s next step development at final is that
not only the estimated treatment effect but also the associated variability are taken into
consideration in the decision making. Simulation studies with sensitivity analyses show that
ASIED achieves desirable operating characteristics. The decision-making criteria proposed
in this paper can be tailored based on users’ risk tolerance. For example, users can calibrate
the hyperparameters ξ1 and ξ2 by their own preferences on risks such as false go risk, false
stop risk, etc. This is critical to precision medicine.
There are several potential extensions. First, functionality of BayRP can be extended to
include an algorithm that can reduce the dimension of the covariate space. This will make
the subgroup identification more powerful and efficient when a large number of potential
predictive biomarkers are available. Second, we can expand BayRP to cover various types of
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outcomes. For example, for survival outcomes we only need to change the sampling model
p(y | zi,Θ,Π). Lastly, we can extend the ASIED to accommodate missing responses and
delayed responses in the case of having an outcome that takes a relatively long time to be
observed.
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TPR TNR
Scenario BayRP LR GUIDE BayRP LR GUIDE
1 0.97 0.54 0.95 1.00 1.00 0.99
2 0.96 0.38 0.89 0.92 0.98 0.89
4 0.87 0.00 0.00 1.00 1.00 0.98
Table 1: The true positive rate (TPR) and true negative rate (TNR) of the subgroup finding
under BayRP, LR, and GUIDE.
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Scenario β0 β1 Truth
1 0.25 2 no effective subgroup
2 0.25 2.55 effective subgroup(>LRV, <TV)
3 0.25 2.83 effective subgroup (=TV)
4 2.6 0 effective all-comers (>LRV, <TV)
5 3.08 0 effective all-comers (=TV)
Table 2: The simulation truths by different values of β0 and β1.
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Interim Analysis
Scenario Truth Pr(All) Pr(Sub) Pr(EarS) Pr(2All) Pr(2Sub)
1 no effective subgroup 0 0.01 0.99 0 0
2 effective subgroup (>LRV, <TV) 0 0.96 0.04 0 0
3 effective subgroup (=TV) 0.1 0.9 0 0 0
4 effective all-comers (>LRV, <TV) 0.95 0 0.05 0 0
5 effective all-comers (=TV) 1 0 0 0 0
Final Recommendation of Go/Stop
Scenario Truth Pr(a=2) Pr(a=1) Pr(a=0)
1 no effective subgroup 0 0 1
2 effective subgroup (>LRV, <TV) 0 0.96 0.04
3 effective subgroup (=TV) 0.06 0.94 0
4 effective all-comers (>LRV, <TV) 0.95 0 0.05
5 effective all-comers (=TV) 1 0 0
Table 3: The operating characteristics of ASIED.
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Start the trial and  
enroll n1 subjects
Continue the trial with original 
population to enroll N-n1 
subjects
Continue the trial with modified 
entry criteria to enroll N-n1 
subjects in the subgroup 
Stop the trial due to futility  
Continue the trial with original  
population and plan a second 
interim with n2 more subjects
Continue the trial with modified  
entry criteria to enroll n2 more 
subjects in the subgroup and 
plan a second interim
Continue the trial with  
the enriched subgroup to 
enroll N-n1-n2 subjects
Continue the trial with original 
population to enroll N-n1-n2 
subjects
Continue the trial with modified 
entry criteria to enroll N-n1-n2 
subjects in the subgroup 
Stop the trial due to futility  
1st interim 2nd interim 
(only needed in some scenarios)
Final Go/Stop recommendation
Recommend Go for all-comers (a=2)
 Recommend Go for subgroup (a=1)
Recommend Stop for the compound (a=0)
Figure 1: A flowchart of the ASIED decision-making framework. The boxes in blue color
represent the final recommendation of Go/Stop.
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Figure 2: An illustration of Π. The example shows that with two rounds of split, the initial
space of two biomarkers is partitioned into four subsets {UU11, UL11, LU12, LL12}.
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Figure 3: From left to right: true effective subgroups in blue for scenarios 1, 2, and 4; the
posterior estimated subgroups represented by grid points in blue under the BayRP, LR, and
GUIDE, respectively.
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Figure 4: Sensitivity analysis of the estimated probabilities of different decision outcomes
at the first interim versus sample sizes. Pr(All) denotes the probability of continuing the
trial with original population until the end of the trial. Pr(Sub) denotes the probability
of continuing the trial with an enriched subpopulation until the end of the trial. Pr(EarS)
denotes the probability of stopping the trial due to futility. Pr(2All) denotes the probability
of continuing the trial with original population and plan a second interim analysis. Pr(2Sub)
denotes the probability of continuing the trial with an enriched subpopulation and plan a
second interim analysis. All probabilities are with respect to 100 repeated simulations.
